ClinicalTrials.gg
WithdrawnNCT05927012Updated Nov 24, 2023

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

A Phase 2 interventional study of KER-047 in Iron Deficiency Anemia, sponsored by Keros Therapeutics, Inc.. Withdrawn at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Keros Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Anemia, Iron-Deficiency with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Anemia, Iron-Deficiency · Israel.

Started
2023
with 1 other
Phase 2
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Keros Therapeutics, Inc.

Among the 10 studies in Anemia, Iron-Deficiency with a site in Israel, this one is one of 2 that started in 2023, is the only one in phase 2, and was the 9th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

1 of the 10 studies in Anemia, Iron-Deficiency with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Anemia, Iron-Deficiency with a site in Israel, or all of them as a file.
02

Study summary

This study aims to explore the safety and preliminary efficacy of a response-guided dose titration of KER-047 in the treatment of functional IDA (Iron deficiency anemia) in MDS (Myelodysplastic syndrome), MF(Myelofibrosis), and MDS/MPN (Myeloproliferative neoplasm) overlap syndromes.

Read the detailed description

This is a Phase 2 multicenter, open-label study being conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of response-guided dose titration of KER-047 in adult participants with functional iron deficiency anemia (IDA) associated with myelodysplastic syndrome (MDS), myelofibrosis (MF), and myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Approximately 20 patients will be enrolled. Dosing of KER-047 may be adjusted based on safety/tolerability and treatment response. The study will be conducted in 2 parts: Part 1 Initial Titration Strategy and Part 2 Cohort Expansion or Alternate Titration Strategy.

The total planned duration of participation for an individual participant is approximately 32 weeks (4-week screening phase, 24-week treatment period, and 4-week follow-up period). For participants in the extension phase, the maximum duration of participation would be approximately 104 weeks (2 years) (4-week screening phase, 24-week treatment period, 18 month [72 weeks] extension period, and 4-week follow-up period).

03

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Functional Iron Deficiency Anemia (Functional IDA)
  • Myelodysplastic Syndromes (MDS)
  • Myelofibrosis (MF)
  • Myelodysplastic Syndrome (MDS)
  • Myeloproliferative Neoplasm Overlap Syndromes (MPN)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years of age, at the time of signing .
  • One of the following:

    1. Diagnosis of MDS according to the 2016 World Health Organization (WHO) classification that meets Revised International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate risk disease with bone marrow blast percentage \<5% within 6 months prior to Day 1 (D1).
    2. Diagnosis of primary myelofibrosis, post polycythemia vera MF, or post-essential thrombocytopenia MF according to the 2017 WHO criteria with bone marrow and peripheral blood blast percentage \<2%, or stable between 2% to 5% over 6 months.
    3. Diagnosis of MDS/MPN overlap syndromes according to the 2016 WHO classification, with bone marrow blast percentage \<5% within 6 months prior to D1.
  • Anemia with iron-restricted erythropoiesis as assessed by laboratory criteria during screening.
  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local study participant privacy regulations.
  • Females of and sexually active males must meet the requirements as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Active infection within 14 days of D1.
  • IPSS-R score indicating high or very high risk MDS, accelerated myelofibrosis (defined as >10% blasts), or diagnosis of acute leukemia.
  • Diagnosis of hemolytic anemia.
  • Diagnosis of porphyria.
  • Anemia due to blood loss 28 days prior to D1.
  • Diagnosis of thalassemia, thalassemia trait, or other hemoglobinopathy.
  • History of drug or alcohol abuse, as defined by the Investigator, within the past 2 years.
  • History of stroke, arterial embolism, or deep venous thrombosis within 6 months prior to D1.
  • Known positive for , active infectious virus or active infectious virus.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part 1 (Initial Titration Strategy)

    KER-047(30 mg, 60mg or 80mg) oral tablet daily (or every other day) for up to 24 weeks.

    Drug: KER-047

  • Experimental
    Part 2 (Cohort Expansion or Alternate Titration Strategy)

    The starting dose regimen and titration schedule of KER-047 oral tablet will be based on the SRC (Safety Review Committee) recommendation from Part 1.

    Drug: KER-047

Interventions

  • DrugKER-047

    Oral tablet, daily (or every other day) administration

06

What researchers measure

Primary outcomes

  1. Percentage of participants experiencing Treatment-emergent adverse events (TEAEs)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  2. Dose limiting toxicities (DLTs)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  3. Percentage of participants experiencing Treatment-related AEs (Adverse events)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  4. Number of participants discontinuing due to AEs (Adverse events)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  5. Change from Baseline in clinical laboratory values

    To determine the safety and tolerability based on changes from baseline in select clinical laboratory parameters including: Alkaline phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Glucose, Potassium, Sodium, Total bilirubin, Folate, WBC count, Platelet Count, Reticulocyte Count, Transferrin Saturation percentage. Note - Select safety parameters will be listed as separate outcomes during results update.

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  6. Systolic Blood Pressure

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  7. Diastolic Blood Pressure

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  8. Respiratory rate

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  9. Heart rate

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  10. Body temperature

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  11. Fridericia corrected QT interval via 12-lead Electrocardiogram (ECG)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  12. QT interval via 12-lead Electrocardiogram (ECG)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  13. QRS interval via 12-lead Electrocardiogram (ECG)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  14. PR interval via 12-lead Electrocardiogram (ECG)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  15. Body weight (in kg)

    To determine safety and tolerability of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

Secondary outcomes

  1. Change from baseline in reticulocyte hemoglobin content (RET-He)

    To evaluate the Pharmacodynamic (PD) effects of KER-047 on iron metabolism in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  2. Change from baseline in hepcidin concentration

    To evaluate the Pharmacodynamic (PD) effects of KER-047 on iron metabolism in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  3. Change from baseline in hemoglobin (Hgb)

    To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  4. Proportion of participants who have Hgb increase of ≥1.0 g/dL (0.6 mmol/L)

    To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  5. Proportion of participants who have Hgb increase of ≥1.5 g/dL (0.9 mmol/L)

    To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks in Part 1 or up to 101 weeks if continuing in the treatment extension

  6. Proportion of RBC-transfused participants who achieve ≥8 weeks of transfusion independence during any consecutive period up to End of Treatment

    To evaluate the effect of KER-047 on anemia in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 29 weeks or up to 101 weeks if in the treatment extension

  7. Plasma KER-047 and any metabolites concentration, summarized by time point

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Week 1 and Week 13 in Part 1 and 2

  8. Estimated peak plasma concentration (Cmax)

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Week 1 and Week 13 in Part 1 and 2

  9. Time to peak plasma concentration (Tmax)

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Week 1 and Week 13 in Part 1 and 2

  10. Area under the plasma KER-047 concentration curve (AUClast)

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Week 1 and Week 13 in Part 1 and 2

  11. Mean trough (Ctrough) plasma KER-047 and metabolites of interest concentration

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 25 weeks

  12. Plasma KER-047 and metabolites of interest accumulation (Rac)

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 25 weeks

  13. Determination of steady-state (as appropriate)

    To evaluate the Pharmacokinetic (PK) of KER-047 in participants with functional IDA associated with MDS, MF, and MDS/MPN overlap syndromes

    Time frame: Up to 25 weeks

07

Study locations

5 sites
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Hadassah University Medical Center
    Jerusalem, 9112001, Israel
  • Galilee Medical Center
    Nahariya, 2633737, Israel
  • Laniado Hospital - Sanz Medical Center
    Netanya, 4244916, Israel
  • Shamir Medical Center (Assaf Harofeh Medical Center)
    Zrifin, 7033001, Israel
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2023; primary completion for Aug 2025, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jul 3, 2023
StartEst.
Nov 30, 2023
Primary completionEst.
Aug 29, 2025
CompletionEst.
Jan 4, 2026
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05927012
Lead sponsor
Keros Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Nov 30, 2023 (estimated)
Primary completion
Aug 29, 2025 (estimated)
Completion
Jan 4, 2026 (estimated)
Last update
Nov 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion